Rossari Biotech Reports Q4 FY26 Results, Highlights 18% Revenue Growth
Mumbai, April 27, 2026: Rossari Biotech Limited, a specialty chemicals manufacturer providing intelligent and sustainable solutions across various industries, today announced its financial results for the quarter and financial year ended March 31, 2026. The company reported strong quarterly and full-year growth across key metrics.The company noted that Q4 FY26 marked its highest-ever quarterly revenue and EBITDA performance.
Q4 FY26 and FY26 Performance Overview
The financial results for the quarter and full year show a positive trend compared to the previous respective periods.Consolidated Q4 FY26 Performance (Compared to Q4 FY25):
Rossari reported revenue from operations growing by 18% to Rs. 684.9 crore, up from Rs. 579.6 crore. EBITDA improved by 11% reaching Rs. 77.3 crore from Rs. 69.5 crore. The Profit After Tax (PAT) increased by 34% to Rs. 46.0 crore from Rs. 34.4 crore. Diluted Earnings Per Share (EPS) stood at Rs. 8.29 compared to Rs. 6.21 in Q4 FY25.
Consolidated FY26 Performance (Compared to FY25):
For the full fiscal year, revenue from operations stood at Rs. 2,396.4 crore, marking a 15% increase over Rs. 2,080.3 crore recorded in FY25. EBITDA saw an 8% increase, reaching Rs. 286.0 crore from Rs. 265.1 crore. PAT grew by 9% to Rs. 149.2 crore, compared to Rs. 136.4 crore in the previous year. Diluted EPS for FY26 was Rs. 26.93 against Rs. 24.63 in FY25.
The financial comparison across quarters and years is presented below:
| Metric (₹ in Crores) | Quarter | Q4 FY25 | Q4 FY26 | Year | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue from Operations | (Cr) | 579.6 | 684.9 | (Cr) | 2,080.3 | 2,396.4 |
| EBITDA | (Cr) | 69.5 | 77.3 | (Cr) | 265.1 | 286.0 |
| PAT | (Cr) | 34.4 | 46.0 | (Cr) | 136.4 | 149.2 |
| Diluted EPS (₹) | - | 6.21 | 8.29 | - | 24.63 | 26.93 |
Operational and Strategic Highlights
In a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, observed that the diversified portfolio and balanced presence across end-user industries helped the company navigate a mixed operating environment. All business segments, including HPPC, TSC, and AHN, demonstrated healthy double-digit growth during the quarter.Regarding capacity expansion, the Unitop commissioned the remaining 15,000 MTPA ethoxylation capacity at its Dahej facility on March 31, 2026. This action increased the total installed ethoxylation capacity to 66,000 MTPA.
The company also detailed its strategic plan, noting that earlier capital expenditure plans announced in April 2025 have been rephased over the next two years to align with evolving business requirements and market conditions, while maintaining the overall strategic intent.
Key Corporate Developments
The company also announced several key corporate developments:- Dividend Declaration: The Board of Directors recommended a dividend of Re. 0.50 per share for the Financial Year 2025-26.
- Research & Development Expansion: Rossari Biotech has established a new Research and Development Facility at Koparkhairane, Navi Mumbai, and simultaneously shifted its existing Research and Development Facility from IIT Bombay.
- Board Appointment: Mr. Udeypaul Singh Gill was appointed as an Additional Director designated as NonExecutive Independent Director of the Company.
(Note: HPPC stands for Home, Personal Care and Performance Chemicals; TSC for Textile Specialty Chemicals; AHN for Animal Health and Nutrition.)
ROSSARI Stock Price Movement
As of 2:03 PM, shares of Rossari Biotech Limited are shedding 6.07% in live trading, currently trading at ₹473.6. The stock has seen a substantial flow, moving on a total volume of 776,024 shares so far today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.